Kymera Therapeutics, Inc. (KYMR)
82.21
-2.29
(-2.71%)
USD |
NASDAQ |
May 15, 16:00
82.23
+0.02
(+0.02%)
After-Hours: 20:00
Kymera Therapeutics EPS Diluted (Quarterly) : -0.7098 for March 31, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Gilead Sciences, Inc. | 1.612 |
| Revolution Medicines, Inc. | -2.291 |
| Catalyst Pharmaceuticals, Inc. | 0.5022 |
| Regeneron Pharmaceuticals, Inc. | 6.752 |
| AbbVie, Inc. | 0.3861 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -69.23M |
| Revenue (Quarterly) | 34.36M |
| Total Expenses (Quarterly) | 103.60M |
| Enterprise Value | 6.192B |
| Gross Profit Margin (Quarterly) | 94.12% |
| Profit Margin (Quarterly) | -201.5% |
| Earnings Yield | -4.34% |
| Normalized Earnings Yield | -4.306 |